Investigators trialed injection of an immune-stimulating substance (poly-ICLC) into the prostate gland using MRI-ultrasound fusion technology in patients scheduled to undergo radical prostatectomy.

The MarketWatch News Department was not involved in the creation of this content. St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC ...

Steve Jones was left with an unwanted side effect after undergoing surgery for prostate cancer: erectile dysfunction that ...

Foresee Pharma gets fourth positive recommendation from DSMB to continue the Casppian Ph3 study, for central precocious puberty: Taipei Friday, February 6, 2026, 18:00 Hrs [IST] F ...

THREE quarters of cancer patients will beat the disease under plans to boost NHS care, Wes Streeting has pledged. He aims to have 75 per cent of those diagnosed from 2035 onwards either cured or ...

The Casppian study design included periodic evaluations and long-term safety monitoring for up to a total of 12 months following the first injection. -- There has been no safety concern with the use ...

“Penis health is measured in many ways, [namely] erectile dysfunction (ED), orgasmic function, libido, satisfaction with ...

Legend Michael Jackson died at the age of 50 on June 25, 2009 after an overdose of numerous medications that he was being ...

Channing Tatum shared he had to undergo surgery over a separated shoulder, sharing x-ray images of the injury before and ...

North East patients are among the first in the UK to trial Lutetium (177Lu) rhPSMA-10.1, a new targeted treatment for advanced prostate cancer resistant to hormone therapy.

President Donald Trump and the Centers for Medicare & Medicaid Services (CMS) recently announced the 15 drugs whose prices ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance ...